Psoriatic arthritis assessment tools in clinical trials
PJ Mease, CE Antoni, DD Gladman… - Annals of the Rheumatic …, 2005 - ard.bmj.com
In order to measure disease activity, progression, and change with therapy in psoriatic arthritis
(PsA), it is important to use accurate, reliable, and feasible outcome measures that can …
(PsA), it is important to use accurate, reliable, and feasible outcome measures that can …
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis …
CE Antoni, A Kavanaugh, B Kirkham… - Arthritis & …, 2005 - Wiley Online Library
… Antoni has received consulting fees of less than $10,000 from Centocor and more than
$10,000 from Schering-Plough. Dr. Kavanaugh has received consulting fees of less than …
$10,000 from Schering-Plough. Dr. Kavanaugh has received consulting fees of less than …
Psoriatic arthritis treatment: biological response modifiers
PJ Mease, CE Antoni - Annals of the Rheumatic Diseases, 2005 - ard.bmj.com
In recent years there has been a surge of interest in the treatment of chronic inflammatory
disorders as a result of the development and application of targeted biological therapies. The …
disorders as a result of the development and application of targeted biological therapies. The …
The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year
A Kavanaugh, CE Antoni, D Gladman… - Annals of the …, 2006 - ard.bmj.com
… Dr Antoni has received consulting fess of less than $10 000 from Centocor and Schering-Plough
and is currently an employee of Schering-Plough. Dr Gladman has received consulting …
and is currently an employee of Schering-Plough. Dr Gladman has received consulting …
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial …
CE Antoni, A Kavanaugh, D Van Der Heijde… - The Journal of …, 2008 - jrheum.org
… CE Antoni, MD, Group Director, Clinical Immunology; B. … Antoni, Schering Plough Research
Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-0530, USA. E-mail: christian.antoni…
Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-0530, USA. E-mail: christian.antoni…
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
…, JR Kalden, JS Smolen, CE Antoni… - Annals of the …, 2002 - ard.bmj.com
As in previous years, the consensus group to consider the use of biological agents was
formed by an organising committee constituted of rheumatologists from the Universities of …
formed by an organising committee constituted of rheumatologists from the Universities of …
[HTML][HTML] An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for …
AE van der Bijl, FC Breedveld, CE Antoni… - Clinical …, 2008 - Springer
This prospective open-label pilot study evaluated the effectiveness and safety of adalimumab
and the relationship to antibodies against infliximab (IFX) in adult patients with active …
and the relationship to antibodies against infliximab (IFX) in adult patients with active …
Standardization of joint examination technique leads to a significant decrease in variability among different examiners
M Grunke, CE Antoni, A Kavanaugh… - The Journal of …, 2010 - jrheum.org
Objective. To reduce the amount of variability among assessors, we conducted joint examination
standardization seminars in conjunction with multicenter clinical trials for patients with …
standardization seminars in conjunction with multicenter clinical trials for patients with …
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)
…, JR Kalden, JS Smolen, CE Antoni… - Annals of the …, 2001 - ard.bmj.com
As last year, the consensus group to consider the use of tumour necrosis factor (TNF)
blocking agents was formed by an organising committee comprising rheumatologists from the …
blocking agents was formed by an organising committee comprising rheumatologists from the …
Longterm outcome of TNF blockade in adult-onset Still's disease
C Dechant, P Schauenberg, CE Antoni… - Deutsche …, 2004 - europepmc.org
Results Seven patients responded to treatment with infliximab. Symptoms like fever,
arthralgia, hepato-splenomegaly and serological parameters instantly improved. Five of these …
arthralgia, hepato-splenomegaly and serological parameters instantly improved. Five of these …